News, views and contacts from the global Drugdevelopment industry
23 May 2017
Industry News

Shire’s lanadelumab and SHP647 meet endpoints in respective trials
Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulcerative colitis.

Albireo to initiate A4250’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

Majority of UC Cases Considered Mild to Moderate
Publication Date: Month 2017 Ulcerative colitis (UC) can be a significant cause of morbidity and worsen the quality of life for individuals with the disease, especially in its most severe form. In UC, the symptoms vary depending on the severity and can include urgent, persistent diarrhea, along with cramping and abdominal pain. Fortunately, in most UC patients, the disease is considered to be mild to moderate, which is associated with milder disease symptoms and improved treatment outcomes compared to severe forms of UC. Figure 1 presents the number of incident cases of UC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), in 2015, by severity class.

Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis
Myovant Sciences has reported positive results from the Phase II clinical trial of relugolix in Japan to treat pain associated with endometriosis in women.

Press Releases

Gamlen Instruments Announces New Company Name
Gamlen Tableting has announced it is changing its trading name from 'Gamlen Tableting' to 'Gamlen Instruments' to acknowledge the company's established global presence as a leader in benchtop powder compaction instrumentation.

Malvern to Host Webinar on Using Multi-Setection size-exclusion chromatography to Evaluate Biosimilarity
Malvern has announced it will be hosting a new webinar presenting size-exclusion chromatography (SEC) data and discussing the impact of different formulations and external stress conditions on Monoclonal antibodies and biosimilar molecules.

Malvern to Host New Webinar on Difference Between Rheometers and Viscometers
Malvern has announced it will host a new webinar discussing the difference between rheometers and viscometer to help viewers decide which of the two is most suitable for their application.

Pharmatest to Host Seven Presentations at AACR in Washington, US
Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US.

Shin-Etsu Purchase Gamlen D Series for Formulation Studies
Provider of a wide range of cellulose ether excipients Shin-Etsu PFMD has purchased a Gamlen D series powder compaction analyser for a laboratory application in Wiesbaden, Germany.

White Papers

Analysing Polysaccharides Using OMNISEC
Malvern notes how moving to multi-detector gel permeation chromatography (GPC) or size-exclusion chromatography (SEC) can provide greater insight than conventional measurements....

Application: Operating Reactor Systems for Process Research and Development
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software...

Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm...

Optimising Development Resources for Efficient Product Development
Development departments suffer from a shortage of resources and are often overburdened with administration...

Top 10 Factors When Choosing a DLS Instrument
The physical components and features of a dynamic light scattering (DLS) instrument, along with the instrument's technical specifications, are important when purchasing a new...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.